Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer

Next Previous
Trial Profile

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SHR 4849 (Primary) ; Durvalumab
  • Indications Malignant melanoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IDEAYA Biosciences

Most Recent Events

  • 05 May 2026 According to IDEAYA Biosciences media release, the company anticipates to provide the clinical update from the trial by the end of 2026.
  • 11 Jan 2026 According to IDEAYA Biosciences media release, initiate clinical combination studies with IDE849 in SCLC, NEC and other DLL3-overexpressing solid tumors in Q2 '26.
  • 15 Dec 2025 Protocol has been amended to include 4 new arms (Experimental: Experimental: Part 1B IDE849 + IDE161 (Dose Escalation), Experimental: Experimental: Part 2 IDE849 Monotherapy (Dose Expansion), Experimental: Experimental: Part 2 IDE849 + durvalumab (Dose Expansion) and Experimental: Experimental: Part 2 IDE849 + IDE161 (Dose Expansion)) , it has changed from 2 to 6.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top